Friday, July 25, 2014   

Japan’s Takeda to appeal US$6b diabetes drug verdict
(04-08 15:53)

A US jury ordered Japan’s Takeda Pharmaceuticals to pay US$6 billion in punitive damages over a diabetes drug, but the country’s biggest drug-maker is challenging the move.
The District Court, Western District Louisiana, on Tuesday also ordered a US$3 billion penalty for co-defendant Eli Lilly, as well as US$1.5 million in compensatory damages.
The legal fight was over Actos, a drug used to treat diabetes, as causing a patient's bladder cancer.
Takeda Senior Vice President Kenneth Greisman said in a statement that Takeda disagrees with the verdict and plans post-trial motions and an appeal.
He said he empathized with the plaintiff but the drug did not cause his cancer.
The drug comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer. –AP

   
Other Business breaking news:
BSkyB to take over Italian, German pay TV networks (30 mins ago)
Russia raises interest rate on geopolitical tensions (41 mins ago)
China adds 7.4m jobs in first half (1 hr 11 mins ago)
German business confidence down in July (1 hr 49 mins ago)
Hang Seng finishes on positive column (2 hrs 23 mins ago)
RBS reports sharp recovery (2 hrs 25 mins ago)
European markets open lower (2 hrs 26 mins ago)
German consumer confidence improves (07-25 14:41)
Nikkei ends at six-month high (07-25 14:27)
Resale home price down in second quarter (07-25 12:42)

More breaking news >>

© 2014 The Standard, The Standard Newspapers Publishing Ltd.
Contact Us | About Us | Newsfeeds | Subscriptions | Print Ad. | Online Ad. | Street Pts

 


Home | Top News | Local | Business | China | ViewPoint | CityTalk | World | Sports | People | Central Station | Spree | Features

The Standard

Trademark and Copyright Notice: Copyright 2014, The Standard Newspaper Publishing Ltd., and its related entities. All rights reserved.  Use in whole or part of this site's content is prohibited.   Use of this Web site assumes acceptance of the
Terms of Use, Privacy Policy Statement and Copyright Policy.  Please also read our Ethics Statement.